Journal Home
Search for

Volume 34, Issue 8, Pages 1260-1266 (August 2008)


View previous. 25 of 53 View next.

Wavefront-guided laser in situ keratomileusis retreatment for consecutive hyperopia and compound hyperopic astigmatism

Simon R. Bababeygy, Christopher I. Zoumalan, MD, Fred Y. Chien, MD, Edward E. Manche, MDCorresponding Author Informationemail address

Accepted 23 March 2008.

Purpose

To evaluate the efficacy, predictability, and safety of wavefront-guided laser in situ keratomileusis (LASIK) using the Visx CustomVue excimer laser (Advanced Medical Optics) in eyes with consecutive hyperopia and compound hyperopic astigmatism after LASIK.

Setting

Stanford University School of Medicine, Department of Ophthalmology, Stanford, California, USA.

Methods

This retrospective analysis included 19 eyes of 16 patients who had wavefront-guided LASIK for consecutive hyperopia and compound hyperopic astigmatism after initial LASIK surgery. Primary outcome variables, including uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), higher-order aberration (HOA) analysis, and spherical equivalence, were evaluated at 1 and 3 months. Nine eyes of 7 patients were available for all visits.

Results

The mean patient age was 51.7 years ± 3.77 (SD) (range 44 to 55 years). The mean preoperative manifest refractive spherical equivalent (MRSE) was 0.99 ± 0.32 diopters (D) (range 0.50 to 1.50 D) and the mean 3-month postoperative MRSE, −0.04 ± 0.66 D (range −1.50 to 0.75 D). At 1 month, 57.9% of eyes had a UCVA of 20/20 or better and 78.9% of 20/25 or better; 84.2% were within ±1.00 D of emmetropia. At 3 months, 66.7% of eyes had a UCVA of 20/20 or better and 88.9% of 20/25 or better; 88.9% were within ±1.00 D of emmetropia. No eye lost 2 or more lines of BSCVA at 1 or 3 months.

Conclusion

Wavefront-guided LASIK was an effective, predictable, and safe procedure for consecutive hyperopia and compound hyperopic astigmatism after LASIK.

From the Department of Ophthalmology (Bababeygy, Zoumalan, Chien, Manche) and Howard Hughes Medical Institute (Bababeygy), Stanford University School of Medicine, Stanford, California, USA

Corresponding Author InformationCorresponding author: Edward E. Manche, MD, Stanford University School of Medicine, Department of Ophthalmology, 900 Blake Wilbur Drive, Room W3002, Stanford, California 94305, USA.

 No author has a financial or proprietary interest in any material or method mentioned.

PII: S0886-3350(08)00515-4

doi:10.1016/j.jcrs.2008.04.026


View previous. 25 of 53 View next.